
Capricor Therapeutics Faces Shareholder Lawsuit After FDA Review
Shares of Capricor Therapeutics plummeted 64.5% on July 27 after the FDA released critical briefing documents regarding the company’s heart therapy, deramiocel. The agency questioned the scientific justification of the firm’s data analysis, prompting the law firm Glancy Prongay Wolke & Rotter LLP to launch a securities fraud investigation.





















